CytomX Therapeutics (CTMX) Prices 14.286M Share Common Offering at $7/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Pre-Open Stock Movers 01/20: (APM) (EVLO) (NFLX) Higher; (GEVO) (HSTO) (BLRX) Lower (more...)
January 20, 2021 9:20 AM ESTPre-Open Stock Movers:
Aptorum Group Limited (NASDAQ: APM) 42.8% HIGHER; announced that the company, through its wholly owned subsidiary, Aptorum International Limited, has received clearance from the Public Health Agency of Canada (Health Canada) regarding the Clinical Trial Application (CTA) to commence a Phase 1 study of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA.
Gevo (NASDAQ: GEVO) 21.6% LOWER; announced that it has entered into definitive agreements... More
After-Hours Stock Movers 01/19: (NFLX) (CKPT) (PCAR) Higher; (HSTO) (BLRX) (ACRX) Lower (more...)
January 19, 2021 5:44 PM ESTAfter-Hours Stock Movers:
Histogen Inc. (NASDAQ: HSTO) 16.5% LOWER; announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that it has additional questions about the companys Investigational New Drug (IND) application package for the planned Phase 1/2 clinical trial of HST-003, which is intended to evaluate the safety and efficacy of human extracellular matrix (hECM:HST-003) implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure.
BioLineRx Ltd. (NASDAQ:... More
CytomX Therapeutics (CTMX) Announces Proposed $75M Common Share Offering
January 19, 2021 4:37 PM ESTCytomX Therapeutics, Inc. (NASDAQ: CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has commenced an underwritten public offering of $75.0 million of its common stock. In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other... More
